Registration Is the Starting Point

A medical device may have U.S. FDA clearance or a European CE mark and still be unable to enter routine commercial distribution in mainland China. It must first follow the applicable Chinese regulatory pathway. Even after receiving a Chinese registration certificate, manufacturers still need to establish a compliant channel, secure hospital demand, compete in procurement and understand whether the clinical procedure can be charged for and reimbursed.

For an overseas manufacturer evaluating China in 2026, the market-entry process is best treated as a sequence of connected decisions: product classification, NMPA registration, commercial representation, hospital purchasing, and procedure economics.

1. Confirm the Chinese Device Classification

China operates a three-class, risk-based medical device system. Class I devices are subject to filing; Class II and III devices require registration. The regulatory authority depends on both the device class and whether it is domestically manufactured or imported.

For imported products, Class I filing and Class II/III registration are handled nationally by the National Medical Products Administration (NMPA). The class assigned by the FDA or under the EU Medical Device Regulation does not automatically determine the Chinese class. Intended use, technical characteristics and the current Chinese classification catalogue are decisive.

Early classification is particularly important for software, artificial intelligence, advanced implants, brain–computer interfaces and surgical robotics, where product definitions and regulatory guidance can evolve.

For a deeper breakdown, read MedChina's existing guide, China Medical Device Classification: NMPA Class I, II and III Explained.

2. Designate the Chinese Regulatory Agent and Prepare the Dossier

Under China's medical device registration and filing rules, an overseas applicant must designate a legal-person enterprise in China to act as its agent. The overseas registrant retains responsibilities for product safety, effectiveness and quality throughout the device lifecycle.

The registration dossier is submitted in Chinese. Depending on the product, it can include technical requirements, product testing, risk analysis, quality-management-system information, labeling and instructions for use, and clinical evaluation materials. Chinese regulations also set requirements concerning evidence of marketing authorization in the country or region of origin, with specified exceptions for qualifying innovative devices.

The regulatory agent and the commercial distributor do not necessarily need to be the same company. The decision should be made with attention to control of registrations, change management, complaints, adverse-event reporting, recalls and long-term commercial relationships.

3. Determine What Clinical Evidence NMPA Requires

The clinical evidence strategy is product-specific. Chinese regulations allow clinical evaluation through relevant clinical literature or data on comparable devices in appropriate circumstances. A clinical trial is necessary when available evidence cannot adequately establish safety and effectiveness. Some devices may qualify for an exemption from clinical evaluation under the applicable rules.

Class III classification does not automatically mean every product must undergo a new clinical trial in China. Conversely, an overseas trial or an existing FDA decision is not an automatic substitute for evidence acceptable to NMPA. The correct path must be determined from the product's intended use, risks and applicable guidance.

For a company deciding whether to invest in China, this evidence assessment should happen before finalizing the commercialization budget. Testing, supplementary technical work and clinical studies can materially alter launch plans.

4. Build a Compliant Distribution and Service Model

Product registration and distribution authorization are different regulatory requirements. As a general rule, distribution of Class III devices requires a license, Class II distribution requires filing, and Class I distribution is not subject to either requirement. Specific exceptions and updated requirements must be checked.

High-value medical equipment also needs more than a qualified seller. Hospitals will assess installation, biomedical engineering support, user training, spare parts, maintenance, software updates and the availability and cost of disposables. For implants and intervention products, physician education, clinical support and supply continuity can be decisive.

A distribution contract should therefore address service responsibilities, regional coverage, regulatory obligations, data and complaint handling, inventory, training and the transition plan if the relationship ends.

5. Understand How Chinese Hospitals Actually Buy Equipment

China's public hospitals are significant purchasers of medical technology, but buying processes vary by device category, hospital, funding source and province. A capital-equipment purchase may proceed from a clinical department's proposed need through technical review, hospital budgeting, procurement approval, tendering, contract award, delivery and acceptance.

Selected large-equipment categories also require hospital configuration authorization. In 2026, Chinese authorities reinforced departmental centralized procurement for specified medical equipment acquired by public institutions with funds subject to the relevant budget-management rules. This does not mean every device is purchased through one nationwide tender.

For overseas companies, the practical implication is that a favorable clinical evaluation and an available hospital budget need to develop in parallel. By the time a public tender is announced, significant work on specifications, budgeting and institutional priorities may already have occurred.

Read MedChina's How Chinese Public Hospitals Buy Medical Devices in 2026 for a detailed purchasing workflow.

6. Evaluate Procedure Pricing and Reimbursement

A hospital's willingness to adopt a technology depends partly on whether it can use the product at a financially sustainable level. Three issues should be assessed separately: whether a medical service price item exists, what a medical institution may charge, and whether the service is reimbursed under medical insurance.

China's National Healthcare Security Administration (NHSA) is standardizing medical service price items. In January 2026 it issued national guidance covering surgical and treatment assistance, including robotic and remote-surgery services. The guidance specifies distinct categories of robotic assistance and links additional charging to the underlying procedure, while local authorities are responsible for implementing prices.

In September 2026, the NHSA launched a plan to develop the first national basic medical insurance catalogue for selected medical service items. The catalogue work is a staged process. A standardized charging item should not be described as automatic nationwide insurance coverage.

For a surgical robot, ultrasound system or interventional technology, procedure utilization, consumable costs, staff training, reimbursement arrangements and hospital budgets can matter as much as the equipment purchase price.

A Short Market-Entry Checklist

Before committing to a China launch, an overseas manufacturer should be able to answer seven questions:

1. What is the product's correct Chinese device classification?

2. Which NMPA registration or filing pathway applies, and what evidence is needed?

3. Who will serve as the Chinese regulatory agent, and how will regulatory responsibilities be managed?

4. Which hospitals and clinical departments have an identifiable need for the product?

5. Which distributors can provide compliant commercial coverage and after-sales service?

6. Does the relevant procedure have a viable pricing and reimbursement pathway?

7. What is the total commercial cost of registration, market development, training, distribution and post-market support?

China remains an important market for specialized and advanced medical technologies. Success depends on aligning regulatory permission, clinical value, hospital decision-making and the economics of routine use.

October 27, 2026